ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)

Xu, Jianming*; Li, Yi; Fan, Qingxia; Shu, Yongqian; Yang, Lei; Cui, Tongjian; Gu, Kangsheng; Tao, Min; Wang, Xiuwen; Cui, Chengxu; Xu, Nong; Xiao, Juxiang; Gao, Quanli; Liu, Yunpeng; Zhang, Tao; Bai, Yuxian; Li, Wei; Zhang, Yiping; Dai, Guanghai; Ma, Dong; Zhang, Jingdong; Bai, Chunmei; Huang, Yunchao; Liao, Wangjun; Wu, Lin; Chen, Xi; Yang, Yan; Wang, Junye; Ji, Shoujian; Zhou, Hui; Wang, Yan; Ma, Zhuo; Wang, Yanqi; Peng, Bo; Sun, Jiya; Mancao, Christoph广东省人民医院; 安徽医科大学; 华中科技大学; 吉林大学; 南方医科大学; 山东大学; 哈尔滨医科大学; 浙江大学; 郑州大学; 苏州大学; 西安交通大学; 中国医科大学; 中国医学科学院; 中国医学科学院北京协和医院; 1; 5
Nature Communications2022-2-14DOI: 10.1038/s41467-022-28408-3
48被引22阅读
引用收藏
分享

摘要

This randomized, open-label, multi-center phase 2 study (NCT03116152) assessed sintilimab, a PD-1 inhibitor, versus chemotherapy in patients with esophageal squamous cell carcinoma after first-line chemotherapy. The primary endpoint was overall survival (OS), while exploratory endpoint was the association of biomarkers with efficacy. The median OS in the sintilimab group was significantly improved compared with the chemotherapy group (median OS 7.2 vs.6.2 months; P = 0.032; HR = 0.70; 95% CI, 0.50-0.97). Incidence of treatment-related adverse events of grade 3-5 was lower with sintilimab than with chemotherapy (20.2 vs. 39.1%). Patients with high T-cell receptor (TCR) clonality and low molecular tumor burden index (mTBI) showed the longest median OS (15.0 months). Patients with NLR < 3 at 6 weeks post-treatment had a significantly prolonged median OS (16.6 months) compared with NLR >= 3. The results demonstrate a significant improvement in OS of sintilimab compared to chemotherapy as second-line treatment for advanced or metastatic ESCC. @@@ Patients with advanced esophageal cancer have poor prognosis and limited treatment options. This randomized, phase II trial compares the efficacy and safety of the anti-PD-1 antibody sintilimab versus chemotherapy in Chinese patients with esophageal squamous cell carcinoma after first-line therapy

学科与关键词

关键词
TO-LYMPHOCYTE RATIO1ST-LINE TREATMENTDOUBLE-BLINDB-CELLSCANCERNEUTROPHILIMMUNOTHERAPYPLATINUMSURVIVALPLUS
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Nature Communications
发表日期
2022-02-14
卷期
第 13 卷, 第 1 期
页码
857
DOI
10.1038/s41467-022-28408-3
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
National Nature Science Foundation of China [82072613]; Innovent Biologics, Inc. - Eli Lilly and Company

作者

  • X

    Xu, Jianming (通讯) (第一作者)

    5 · chinese peoples liberat army gen hosp

  • L

    Li, Yi

    5 · chinese peoples liberat army gen hosp

查看全部 36 位作者收起作者
  • F

    Fan, Qingxia

    1 · zhengzhou univ

  • S

    Shu, Yongqian

    1 · nanjing med univ

  • Y

    Yang, Lei

    nantong tumor hosp

  • C

    Cui, Tongjian

    fujian prov hosp

  • G

    Gu, Kangsheng

    1 · anhui med univ

  • T

    Tao, Min

    1 · soochow univ

  • W

    Wang, Xiuwen

    shandong univ

  • C

    Cui, Chengxu

    chinese acad med sci · peking union med coll

  • X

    Xu, Nong

    1 · zhejiang univ

  • X

    Xiao, Juxiang

    1 · xi an jiao tong univ

  • G

    Gao, Quanli

  • L

    Liu, Yunpeng

    1 · china med univ

  • Z

    Zhang, Tao

    huazhong univ sci & technol

  • B

    Bai, Yuxian

    harbin med univ

  • L

    Li, Wei

    jilin univ

  • Z

    Zhang, Yiping

    zhejiang canc hosp

  • D

    Dai, Guanghai

    chinese peoples liberat army gen hosp

  • M

    Ma, Dong

    guangdong prov peoples hosp

  • Z

    Zhang, Jingdong

    liaoning canc hosp

  • B

    Bai, Chunmei

    chinese acad med sci · peking union med coll hosp

  • H

    Huang, Yunchao

    1

  • L

    Liao, Wangjun

    southern med univ

  • W

    Wu, Lin

    hunan canc hosp

  • C

    Chen, Xi

  • Y

    Yang, Yan

  • W

    Wang, Junye

    jining med univ

  • J

    Ji, Shoujian

    5 · chinese peoples liberat army gen hosp

  • Z

    Zhou, Hui

  • W

    Wang, Yan

  • M

    Ma, Zhuo

  • W

    Wang, Yanqi

  • P

    Peng, Bo

  • S

    Sun, Jiya

  • M

    Mancao, Christoph

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417